Latent and lytic Epstein-Barr virus replication strategies

Reviews in Medical Virology

Volumn 15, Issue 1, 2005, Pages 3-15

  Tsurumi, Tatsuya ^a   Fujita, Masatoshi ^a,b   Kudoh, Ayumi ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIS ACTING ELEMENT; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; EPSTEIN BARR VIRUS ANTIGEN; GENOMIC DNA; INITIATION FACTOR; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; PROTEIN ORIP; PROTEIN P16INK4A; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

APOPTOSIS; B LYMPHOCYTE; BRLF1 GENE; BZLF1 GENE; CELL CYCLE; CELL NUCLEUS; CONFOCAL MICROSCOPY; EPSTEIN BARR VIRUS; HERPES VIRUS; IMMEDIATE EARLY GENE; LYMPHOBLASTOID CELL LINE; NONHUMAN; PLASMID; PROTEIN PHOSPHORYLATION; REVIEW; VIRUS LATENCY; VIRUS REPLICATION;

CELL CYCLE; DNA REPLICATION; DNA, VIRAL; DNA-BINDING PROTEINS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; MODELS, BIOLOGICAL; TRANS-ACTIVATORS; VIRAL PROTEINS; VIRUS LATENCY; VIRUS REPLICATION;

EID: 11244266124     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.441     Document Type: Review

References (81)

1. Fields BN, Knipe DM, Howley PM, et al. Fields Virology, 4th edn. Lippincott Williams & Wilkins: Philadelphia, PA; 2002.
2. Faulkner GC, Krajewski AS, Crawford DH. The ins and outs of EBV infection. Trends Microbiol 2000; 8: 185-189.
3. Hammerschmidt W, Sugden B. Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell 1988; 55: 427-433.
4. Fixman ED, Hayward GS, Hayward SD. Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays. J Virol 1995; 69: 2998-3006.
5. Dyson PJ, Farrell PJ. Chromatin structure of Epstein-Barr virus. J Gen Virol 1985; 66: 1931-1940.
6. Adams A. Replication of latent Epstein-Barr virus genomes in Raji cells. J Virol 1987; 61: 1743-1746.
7. Kirchmaier AL, Sugden B. Plasmid maintenance of derivatives of oriP of Epstein-Barr virus. J Virol 1995; 69: 1280-1283.
8. Yates J, Warren N, Reisman D, et al. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 1984; 81: 3806-3810.
9. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
10. Rawlins DR, Milman G, Hayward SD, et al. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 1985; 42: 859-868.
11. Krysan PJ, Haase SB, Calos MP. Isolation of human sequences that replicate autonomously in human cells. Mol Cell Biol 1989; 9: 1026-1033.
12. Aiyar A, Tyree C, Sugden B. The plasmid replicon of EBV consists of multiple cis-acting elements that facilitate DNA synthesis by the cell and a viral maintenance element. EMBO J 1998; 17: 6394-6403.
13. Hung SC, Kang MS, Kieff E. Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1. Proc Natl Acad Sci USA 2001; 98: 1865-1870.
14. Kanda T, Otter M, Wahl GM. Coupling of mitotic chromosome tethering and replication competence in Epstein-Barr virus-based plasmids. Mol Cell Biol 2001; 21: 3576-3588.
15. Gahn TA, Schildkraut CL. The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication. Cell 1989; 58: 527-535.
16. Harrison S, Fisenne K, Hearing J. Sequence requirements of the Epstein-Barr virus latent origin of DNA replication. J Virol 1994; 68: 1913-1925.
17. Shirakata M, Hirai K. Identification of minimal oriP of Epstein-Barr virus required for DNA replication. J Biochem (Tokyo) 1998; 123: 175-181.
18. Norio P, Schildkraut CL, Yates JL. Initiation of DNA replication within oriP is dispensable for stable replication of the latent Epstein-Barr virus chromosome after infection of established cell lines. J Virol 2000; 74: 8563-8574.
19. Yates JL, Camiolo SM, Bashaw JM. The minimal replicator of Epstein-Barr virus oriP. J Virol 2000; 74: 4512-4522.
20. Little RD, Schildkraut CL. Initiation of latent DNA replication in the Epstein-Barr virus genome can occur at sites other than the genetically defined origin. Mol Cell Biol 1995; 15: 2893-2903.
21. Norio P, Schildkraut CL. Visualization of DNA replication on individual Epstein-Barr virus episomes. Science 2001; 294: 2361-2364.
22. Yates JL, Guan N. Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. J Virol 1991; 65: 483-488.
23. Frappier L, O'Donnell M. Overproduction, purification, and characterization of EBNA1, the origin binding protein of Epstein-Barr virus. J Biol Chem 1991; 266: 7819-7826.
24. Dhar SK, Yoshida K, Machida Y, et al. Replication from oriP of Epstein-Barr virus requires human ORC and is inhibited by geminin. Cell 2001; 106: 287-296.
25. Diffley JF. Once and only once upon a time: specifying and regulating origins of DNA replication in eukaryotic cells. Genes Dev 1996; 10: 2819-2830.
26. Fujita M. Cell cycle regulation of DNA replication initiation proteins in mammalian cells. Front Biosci 1999; 4: D816-D823.
27. Chaudhuri B, Xu H, Todorov I, et al. Human DNA replication initiation factors, ORC and MCM, associate with oriP of Epstein-Barr virus. Proc Natl Acad Sci USA 2001; 98: 10085-10089.
28. Schepers A, Ritzi M, Bousset K, et al. Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein-Barr virus. EMBO J 2001; 20: 4588-4602.
29. Burhans WC, Huberman JA. DNA replication origins in animal cells: a question of context? Science 1994; 263: 639-640.
30. Masukata H, Satoh H, Obuse C, et al. Autonomous replication of human chromosomal DNA fragments in human cells. Mol Biol Cell 1993; 4: 1121-1132.
31. Krysan PJ, Calos MP. Replication initiates at multiple locations on an autonomously replicating plasmid in human cells. Mol Cell Biol 1991; 11: 1464-1472.
32. Santocanale C, Diffley JF. ORC- and Cdc6-dependent complexes at active and inactive chromosomal replication origins in Saccharomyces cerevisiae. EMBO J 1996; 15: 6671-6679.
33. Pfuller R, Hammerschmidt W. Plasmid-like replicative intermediates of the Epstein-Barr virus lytic origin of DNA replication. J Virol 1996; 70: 3423-3431.
34. Schepers A, Pich D, Hammerschmidt W. Activation of oriLyt, the lytic origin of DNA replication of Epstein-Barr virus, by BZLF1, Virology 1996; 220: 367-376.
35. Tsurumi T, Kobayashi A, Tamai K, et al. Functional expression and characterization of the Epstein-Barr virus DNA polymerase catalytic subunit. J Virol 1993; 67: 4651-4658.
36. Tsurumi T. Purification and characterization of the DNA-binding activity of the Epstein-Barr virus DNA polymerase accessory protein BMRF1 gene products, as expressed in insect cells by using the baculovirus system. J Virol 1993; 67: 1681-1687.
37. Tsurumi T, Daikoku T, Kurachi R, et al. Functional interaction between Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit in vitro. J Virol 1993; 67: 7648-7653.
38. Tsurumi T, Daikoku T, Nishiyama Y. Further characterization of the interaction between the Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit with regard to the 3′-to-5′ exonucleolytic activity and stability of initiation complex at primer terminus. J Virol 1994; 68: 3354-3363.
39. Tsurumi T, Kishore J, Yokoyama N, et al. Overexpression, purification and helix-destabilizing properties of Epstein-Barr virus ssDNA-binding protein. J Gen Virol 1998; 79: 1257-1264.
40. Tsurumi T, Yamada H, Daikoku T, et al. Strand displacement associated DNA synthesis catalyzed by the Epstein-Barr virus DNA polymerase. Biochem Biophys Res Commun 1997; 238: 33-38.
41. Fujii K, Yokoyama N, Kiyono T, et al. The Epstein-Barr virus pol catalytic subunit physically interacts with the BBLF4-BSLF1-BBLF2/3 complex. J Virol 2000; 74: 2550-2557.
42. Yokoyama N, Fujii K, Hirata M, et al. Assembly of the Epstein-Barr virus BBLF4, BSLF1 and BBLF2/3 proteins and their interactive properties. J Gen Virol 1999; 80: 2879-2887.
43. Tsurumi T. EBV replication enzymes. Curr Top Microbiol Immunol 2001; 258: 65-87.
44. Baumann M, Feederle R, Kremmer E, et al. Cellular transcription factors recruit viral replication proteins to activate the Epstein-Barr virus origin of lytic DNA replication, oriLyt. EMBO J 1999; 18: 6095-6105.
45. Gao Z, Krithivas A, Finan JE, et al. The Epstein-Barr virus lytic transactivator Zta interacts with the helicase-primase replication proteins. J Virol 1998; 72: 8559-8567.
46. Zhang Q, Hong Y, Dorsky D, et al. Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication. J Virol 1996; 70: 5131-5142.
47. Packham G, Economou A, Rooney CM, et al. Structure and function of the Epstein-Barr virus BZLF1 protein. J Virol 1990; 64: 2110-2116.
48. Adamson AL, Kenney S. The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. J Virol 1999; 73: 6551-6558.
49. Farrell PJ, Allan GJ, Shanahan F, et al. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 1991; 10: 2879-2887.
50. Kudoh A, Fujita M, Kiyono T, et al. Reactivation of lytic replication from B cells latently infected with Epstein-Barr virus occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication. J Virol 2003; 77: 851-861.
51. Cayrol C, Flemington EK. The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J 1996; 15: 2748-2759.
52. Rodriguez A, Jung EJ, Yin Q, et al. Role of c-myc regulation in Zta-mediated induction of the cyclin-dependent kinase inhibitors p21 and p27 and cell growth arrest. Virology 2001; 284: 159-169.
53. Flemington EK. Herpesvirus lytic replication and the cell cycle: arresting new developments. J Virol 2001; 75:4475-4481.
54. Zhang Q, Gutsch D, Kenney S. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol 1994; 14: 1929-1938.
55. Kato J. Induction of S phase by G1 regulatory factors. Front Biosci 1999; 4: D787-D792.
56. Krude T, Jackman M, Pines J, et al. Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system. Cell 1997; 88: 109-119.
57. Cardoso MC, Leonhardt H, Nadal-Ginard B. Reversal of terminal differentiation and control of DNA replication: cyclin A and Cdk2 specifically localize at subnuclear sites of DNA replication. Cell 1993; 74: 979-992.
58. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000; 14: 2393-2409.
59. Gray NS, Wodicka L, Thunnissen AM, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998; 281: 533-538.
60. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243: 527-536.
61. Kudoh A, Daikoku T, Sugaya Y, et al. Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication. J Virol 2004; 78: 104-115.
62. Liu C, Sista ND, Pagano JS. Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F. J Virol 1996; 70: 2545-2555.
63. Mauser A, Holley-Guthrie E, Zanation A, et al. The Epstein-Barr virus immediate-early protein BZLF1 induces expression of E2F-1 and other proteins involved in cell cycle progression in primary keratinocytes and gastric carcinoma cells. J Virol 2002; 76: 12543-12552.
64. Swenson JJ, Mauser AE, Kaufmann WK, et al. The Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction. J Virol 1999; 73: 6540-6550.
65. Adams PD, Kaelin WG, Jr. Transcriptional control by E2F. Semin Cancer Biol 1995; 6: 99-108.
66. Ragoczy T, Miller G. Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites. J Virol 2001; 75: 5240-5251.
67. Nicolas M, Noe W, Ciudad CJ. Transcriptional regulation of the human SP1 gene promoter by SP-family members, NF-Y and E2F. Biochem J 2003; 371: 265-275.
68. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992; 258: 424-439.
69. de Bruyn Kops A, Knipe DM. Formation of DNA replication structures in herpes virus-infected cells requires a viral DNA binding protein. Cell 1988; 55: 857-868.
70. Ehmann GL, McLean TI, Bachenheimer SL. Herpes simplex virus type 1 infection imposes a G(1)/S block in asynchronously growing cells and prevents G(1) entry in quiescent cells. Virology 2000; 267: 335-349.
71. Song B, Liu JJ, Yeh KC, et al. Herpes simplex virus infection blocks events in the G1 phase of the cell cycle. Virology 2000; 267: 326-334.
72. Cai W, Schaffer PA. A cellular function can enhance gene expression and plating efficiency of a mutant defective in the gene for ICP0, a transactivating protein of herpes simplex virus type 1. J Virol 1991; 65: 4078-4090.
73. Ralph WM, Jr, Cabatingan MS, Schaffer PA. Induction of herpes simplex virus type 1 immediate-early gene expression by a cellular activity expressed in Vero and NB41A3 cells after growth arrest-release. J Virol 1994; 68: 6871-6882.
74. Jordan R, Schang L, Schaffer PA. Transactivation of herpes simplex virus type 1 immediate-early gene expression by virion-associated factors is blocked by an inhibitor of cyclin-dependent protein kinases. J Virol 1999; 73: 8843-8847.
75. Schang LM, Phillips J, Schaffer PA. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J Virol 1998; 72: 5626-5637.
76. Bresnahan WA, Boldogh I, Chi P, et al. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology 1997; 231: 239-247.
77. Poma EE, Kowalik TF, Zhu L, et al. The human cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves p107-mediated transcriptional repression of an E2F-responsive promoter. J Virol 1996; 70: 7867-7877.
78. Hagemeier C, Caswell R, Hayhurst G, et al. Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein. EMBO J 1994; 13: 2897-2903.
79. Feng WH, Israel B, Raab-Traub N, et al. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 2002; 62: 1920-1926.
80. Westphal EM, Blackstock W, Feng W, et al. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res 2000; 60: 5781-5788.
81. Mentzer SJ, Perrine SP, Faller DV. Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis 2001; 3: 177-185.